{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:35:37Z","timestamp":1789932937089,"version":"4.0.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174728","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T18:38:24Z","timestamp":1490985504000},"page":"e0174728","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform"],"prefix":"10.1371","volume":"12","author":[{"given":"Nadine C.","family":"Salisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7041","authenticated-orcid":true,"given":"Marija","family":"Vujadinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"van der Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Vorthoren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmjan","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jort","family":"Vellinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"issue":"22","key":"ref1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-11-62","article-title":"Phase 1 studies of the safety and immunogenicity of electroporated HER2\/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors","volume":"11","author":"CM Diaz","year":"2013","journal-title":"Journal of translational medicine"},{"issue":"205","key":"ref3","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"F Smaill","year":"2013","journal-title":"Science translational medicine"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"SM Sumida","year":"2004","journal-title":"Journal of virology"},{"issue":"9653","key":"ref5","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"DH Barouch","year":"2004","journal-title":"Journal of immunology"},{"issue":"32","key":"ref7","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"DH Barouch","journal-title":"Vaccine"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"DA Stanley","year":"2014","journal-title":"Nature medicine"},{"issue":"44","key":"ref9","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1016\/j.vaccine.2009.07.106","article-title":"Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys","volume":"27","author":"A Rodriguez","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/CVI.00311-10","article-title":"The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert","volume":"17","author":"K Radosevic","year":"2011","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"A Ouedraogo","year":"2013","journal-title":"PloS one"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"E Soler","year":"2007","journal-title":"Biotechnol Annu Rev"},{"issue":"24","key":"ref13","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji ST Rts SCTP","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"KE Kester","year":"2009","journal-title":"The Journal of infectious diseases"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/651025","article-title":"Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults","volume":"201","author":"AI Olotu","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1128\/IAI.01879-06","article-title":"Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S\/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone","volume":"75","author":"VA Stewart","year":"2007","journal-title":"Infection and immunity"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp100214b","article-title":"Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach","volume":"8","author":"QL Matthews","year":"2011","journal-title":"Mol Pharm"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1128\/JVI.02667-05","article-title":"Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity","volume":"80","author":"A Krause","year":"2006","journal-title":"Journal of virology"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/j.1460-2075.1989.tb08528.x","article-title":"Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography","volume":"8","author":"PS Furcinitti","year":"1989","journal-title":"The EMBO journal"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JVI.56.2.439-448.1985","article-title":"Molecular composition of the adenovirus type 2 virion","volume":"56","author":"J van Oostrum","year":"1985","journal-title":"Journal of virology"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ymthe.2004.01.012","article-title":"Use of adenovirus protein IX (pIX) to display large polypeptides on the virion\u2014generation of fluorescent virus through the incorporation of pIX-GFP","volume":"9","author":"RA Meulenbroek","year":"2004","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2310\/7290.2006.00029","article-title":"Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion","volume":"5","author":"QL Matthews","year":"2006","journal-title":"Molecular imaging"},{"issue":"14","key":"ref23","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/JVI.76.14.6893-6899.2002","article-title":"Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX","volume":"76","author":"IP Dmitriev","year":"2002","journal-title":"Journal of virology"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/JVI.78.7.3470-3479.2004","article-title":"Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX","volume":"78","author":"J Vellinga","year":"2004","journal-title":"Journal of virology"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1128\/JVI.01840-09","article-title":"Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection","volume":"84","author":"W Bayer","journal-title":"Journal of virology"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/hum.2009.148","article-title":"Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid","volume":"21","author":"JL Boyer","year":"2010","journal-title":"Human gene therapy"},{"issue":"35","key":"ref27","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.vaccine.2007.06.019","article-title":"Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant","volume":"25","author":"OJ Ophorst","year":"2007","journal-title":"Vaccine"},{"issue":"15","key":"ref28","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"R Vogels","year":"2003","journal-title":"Journal of virology"},{"issue":"1","key":"ref29","first-page":"115","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"JV Maizel Jr.","year":"1968","journal-title":"Virology"},{"issue":"Pt 8","key":"ref30","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1099\/vir.0.81956-0","article-title":"Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells","volume":"87","author":"M Havenga","year":"2006","journal-title":"The Journal of general virology"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/hum.2007.085","article-title":"Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors","volume":"18","author":"M Nakai","year":"2007","journal-title":"Human gene therapy"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","article-title":"Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response","volume":"76","author":"V Molinier-Frenkel","year":"2002","journal-title":"Journal of virology"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1084\/jem.164.6.1915","article-title":"Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro","volume":"164","author":"SB Aley","year":"1986","journal-title":"J Exp Med"},{"issue":"39","key":"ref34","doi-asserted-by":"crossref","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","article-title":"Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate","volume":"284","author":"ML Plassmeyer","year":"2009","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.immuni.2007.06.007","article-title":"B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node","volume":"27","author":"YR Carrasco","year":"2007","journal-title":"Immunity"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1073\/pnas.79.2.395","article-title":"Specific cellular stimulation in the primary immune response: a quantized model","volume":"79","author":"B Vogelstein","year":"1982","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/10430340152712683","article-title":"The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid","volume":"13","author":"JN Higginbotham","year":"2002","journal-title":"Human gene therapy"},{"issue":"50","key":"ref38","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"DE Zak","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"A Le Bon","year":"2003","journal-title":"Nat Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1742-4690-8-75","article-title":"Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes","volume":"8","author":"W Bayer","year":"2011","journal-title":"Retrovirology"},{"issue":"18","key":"ref41","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"JE Teigler","journal-title":"Journal of virology"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"N Tatsis","year":"2004","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"20","key":"ref43","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"DR Casimiro","year":"2004","journal-title":"Journal of virology"},{"issue":"7\u20138","key":"ref44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(01)00450-9","article-title":"Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes","volume":"20","author":"SC Gilbert","year":"2002","journal-title":"Vaccine"},{"issue":"14","key":"ref45","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1128\/JVI.78.14.7490-7497.2004","article-title":"Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys","volume":"78","author":"NL Letvin","year":"2004","journal-title":"Journal of virology"},{"issue":"6869","key":"ref46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"JW Shiver","year":"2002","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T20:01:40Z","timestamp":1601841700000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174728"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174728","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,31]]}}}